Form 4: Plus Therapeutics Director Greg Petersen Buys $16,875 in Company Stock
SEC Form 4 Filing
Director Greg Petersen increased his holdings in Plus Therapeutics by purchasing 12,500 shares of common stock at $1.35 per share on September 11, 2024.
Summary
- On September 11, 2024, Greg Petersen, a director of Plus Therapeutics, Inc. (PSTV), purchased 12,500 shares of the company's common stock.
- The purchase price was $1.35 per share.
- Following the transaction, Petersen directly owns 48,921 shares of Plus Therapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the transaction is relatively small and may not be highly significant.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, but should be considered alongside other factors when evaluating the company.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/11/2024 | Date of transaction: Greg Petersen purchased 12,500 shares of Plus Therapeutics stock. |
| 09/13/2024 | Date of signature on the Form 4 filing. |
Keywords
Plus Therapeutics, PSTV, Greg Petersen, stock purchase, director, Form 4, beneficial ownership, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.